Evaluating “Brain Permeability”: A Critical Issue for the Development of Therapeutic Agents for Primary and Metastatic Brain Tumors
Cet article présente les réponses aux questions soulevées lors d'une réunion de travail, organisée conjointement par l'"Adult Brain Tumor Consortium" et la "Food and Drug Administration", pour identifier les critères permettant d'évaluer la perméabilité de la barrière hémato-encéphalique dans le cadre de tumeurs primitives ou métastatiques du système nerveux central
Current assessments of brain permeability rely predominantly on drug delivery to contrast-enhancing tumor regions. However, substantial portions of central nervous system (CNS) tumors reside within non-enhancing brain (NEB), where drug concentrations frequently remain subtherapeutic. This collaborative Adult Brain Tumor Consortium and Food and Drug Administration workshop aimed to identify criteria for defining NEB permeability to accomplish two critical objectives: 1) allocate clinical trial resources toward agents achieving therapeutic NEB concentrations and 2) minimize systemic toxicity when CNS benefit is improbable. The workshop systematically evaluated permeability assessment modalities, including drug physicochemical properties, in vitro blood-brain barrier models, and penetration into cerebrospinal fluid and normal rodent brain. Methodological approaches to determine requisite NEB drug concentrations and approaches to measuring NEB pharmacokinetics and pharmacodynamics were examined. This culminated in developing the Non-Enhancing Brain Permeability Index (NEBPI), which assigns therapeutic agents to three categories: sufficiently permeable, insufficiently permeable, or impermeable. The NEBPI provides a standardized framework to assist investigators and regulatory agencies to evaluate NEB penetration before human efficacy studies are initiated for agents that require direct tumor contact. Assessing NEB drug penetration is critical to improving outcomes in CNS tumors and reducing the incidence of brain metastases in systemic malignancies.
Neuro-Oncology , article en libre accès, 2026